Epigenetic biomarkers of progestin-resistance in endometriosis - PubMed
5 hours ago
- #Epigenetics
- #Endometriosis
- #Progestin-resistance
- Endometriosis affects up to 15% of reproductive-age women and is often treated with progestin-based therapies.
- Approximately one-third of patients exhibit progestin resistance, leading to inadequate symptom relief.
- The study aimed to identify circulating leukocyte DNA methylation signatures as non-invasive biomarkers for progestin treatment response.
- A prospective cohort study of 31 women with endometriosis categorized as progestin responders (n=10) or non-responders (n=21).
- Whole-genome methylation analysis identified 1,439 differentially methylated genes between responders and non-responders.
- A three-gene methylation signature (MMP20, NRXN1, RNA5-8SN5) distinguished responders from non-responders with high accuracy (ROC AUC = 0.952).
- Internal validation confirmed the robustness of the model (bootstrap AUC = 0.907, 95% CI: 0.80–0.957; permutation p < 0.001).
- Blood-based epigenetic profiling may help personalize treatment decisions and avoid ineffective therapy.